Silk Cotton Stem Bark: Cardiovascular, Bone and Metabolic Research
The stem bark of Bombax ceiba carries the most chemically varied research of any single part of this tree — a genuinely different compound catalogue from the leaf, and results touching blood pressure, bone density and metabolic syndrome that the main hub page does not cover. All of it is preclinical: rat and cell-line work, none of it in people. This page also untangles a naming trap the bark itself created: a bark compound called shamiminol is not the same molecule, from the same part, as the leaf compound shamimin already described on the hub — despite the near-identical name and the same research group publishing both.
Table of Contents
- Shamimin Is Not Shamiminol: Two Compounds, Two Parts, One Confusing Name
- Bark-Derived Hypotensive Constituents (Saleem 2003)
- Antibacterial and Antioxidant Screening of the Bark
- Bone: Osteoblast Proliferation and Anti-Osteoporotic Activity
- Metabolic Syndrome: FAS and PTP-1B Modulation Against High-Fat-Diet Obesity
- Bark Extract as a Nanoparticle-Synthesis Platform
- Reading These Findings Together, Honestly
- Cautions and Practical Guidance
- Key Research Papers
- Connections
Shamimin Is Not Shamiminol: Two Compounds, Two Parts, One Confusing Name
The hub page for this plant already covers shamimin, a flavonol C-glycoside isolated from Bombax ceiba leaves and reported in 1999 to lower blood pressure and blood glucose in animals. Twelve years later, the same research group (Faizi and colleagues) isolated a different compound from a different part — the stem bark — and named it shamiminol: an aromatic glycoside, structurally a trimethoxyphenol xylopyranosyl-glucopyranoside, chemically unrelated in class to the flavonol shamimin. The 2011 paper describing shamiminol is a pure structural-chemistry report — NMR and mass spectrometry to establish the molecule's structure — and includes no pharmacological testing whatsoever. No blood pressure data, no blood glucose data, no bioactivity of any kind has been published for shamiminol.
This is worth stating plainly because it is exactly the kind of trap this site's evidence standards exist to catch: two compounds from the same tree, isolated by the same chemists, with names differing by two letters, from two different parts, with two completely different evidence profiles — one has an old but real pharmacological result (leaf, shamimin, animal hypotensive/hypoglycemic data), and the other has a structure and nothing else (bark, shamiminol, chemistry only). Citing shamiminol as if it shared shamimin's activity data would be a fabrication, not a rounding error.
Bark-Derived Hypotensive Constituents (Saleem 2003)
Separately from shamiminol, the same research group published an earlier 2003 paper in Biological & Pharmaceutical Bulletin specifically examining constituents isolated from Bombax ceiba stem bark for hypotensive activity and toxicology — a genuine, if preliminary, bark-specific pharmacological finding, distinct from both the leaf shamimin work and the structure-only shamiminol paper. As with the leaf finding, this is animal pharmacology: a blood-pressure effect measured acutely in anaesthetised or restrained animals, not a chronic oral-dosing study and not remotely a substitute for prescribed antihypertensive therapy. What it establishes is that the bark, like the leaf, contains constituents that are pharmacologically active on blood pressure in principle — a different, additional line of preclinical evidence to the leaf work already on the hub, not a repeat of it.
Antibacterial and Antioxidant Screening of the Bark
Stem bark extracts have been screened for antimicrobial activity in at least two independent studies. A 2017 paper from a Pakistani group tested stem bark extracts collected in South Punjab for antibacterial and antioxidant potential; a 2018 paper (Shah and colleagues, Pakistan Journal of Pharmaceutical Sciences) ran a broader phytochemical screen of stem bark methanol, ethanol and aqueous extracts by disc diffusion against several bacterial species, reporting inhibition of Pseudomonas aeruginosa, Bacillus subtilis, Xanthomonas maltophilia and Escherichia coli at varying concentrations, with Klebsiella pneumoniae resistant to all three extract types tested.
These are standard disc-diffusion laboratory screens — useful for flagging that a plant contains antimicrobial chemistry worth further study, and a long way from establishing that a bark decoction can treat an infection. Disc-diffusion zone-of-inhibition data does not translate directly into a systemic or topical dose, and no animal infection model or human trial has followed up on either paper.
Bone: Osteoblast Proliferation and Anti-Osteoporotic Activity
The most methodologically developed bark study concerns bone. Chauhan and colleagues (BMC Complementary and Alternative Medicine, 2018) tested petroleum-ether and methanolic extracts of Bombax ceiba stem bark in two linked experiments:
- In vitro: both extracts significantly increased osteoblast (bone-forming cell) proliferation and alkaline phosphatase activity in the UMR-106 rat osteosarcoma cell line, a standard (non-human) osteoblast model.
- In vivo: female Wistar rats underwent surgical ovariectomy (removal of the ovaries, the standard rodent model for postmenopausal bone loss) and were then treated for 28 days with bark extract at 100 or 200 mg/kg, alongside a group given raloxifene — a real, FDA-approved selective estrogen receptor modulator used clinically to prevent postmenopausal osteoporosis — at 1 mg/kg as an active comparator. Both bark-extract doses significantly reduced the bone mineral density loss, bone-strength loss, and histological bone destruction that ovariectomy otherwise produces, and significantly restored serum alkaline phosphatase, calcium, phosphorus and estradiol toward normal.
The authors propose an estrogenic mechanism, consistent with the extract restoring serum estradiol levels in the ovariectomized animals, and quantified lupeol, gallic acid and β-sitosterol in the extracts by HPLC/HPTLC as candidate active constituents.
What this is, and is not. This is a well-designed rat study with a real drug comparator, which is more rigorous than most of the preclinical literature on this plant. It is still a single rat study, in one animal model of one specific condition (surgical estrogen withdrawal), that has not been replicated by an independent group and has never been tested in a human bone-density trial. Comparison against raloxifene establishes that the assay can detect a clinically meaningful anti-osteoporotic signal (the model is validated by the fact raloxifene worked in it) — it does not establish that the bark extract works as well as raloxifene in people, which would require a head-to-head human trial this plant does not have.
Metabolic Syndrome: FAS and PTP-1B Modulation Against High-Fat-Diet Obesity
Gupta and colleagues (BMC Complementary and Alternative Medicine, 2013) fed male Wistar rats a high-fat diet for ten weeks to induce experimental obesity, then treated animals from week seven through week ten with methanolic extract of Bombax ceiba stem bark (100, 200 or 400 mg/kg) or gemfibrozil (a real, prescribed fibrate drug used to lower triglycerides) at 50 mg/kg as an active comparator.
High-fat feeding produced the expected derangements: significant increases in body weight, BMI, serum glucose, triglycerides, LDL, VLDL, cholesterol, free fatty acids and liver enzymes, alongside a significant drop in HDL. Both bark extract and gemfibrozil significantly reversed these changes relative to untreated high-fat-diet controls, and the paper reports the 200 and 400 mg/kg bark-extract doses produced a more pronounced effect than the gemfibrozil comparator on several measures. The proposed mechanism is inhibition of FAS (fatty acid synthase) and PTP-1B (protein tyrosine phosphatase 1B, a negative regulator of insulin signaling), attributed to the bark's lupeol and flavonoid content.
Read the "beat the drug" result carefully. A positive-control comparator exists in a study like this to confirm the model is behaving as expected — it validates that the assay can detect a real metabolic effect, which it did, for both arms. It is a substantially weaker basis for concluding the plant extract outperforms the drug in general: the comparator dose (50 mg/kg gemfibrozil) may not represent that drug's optimized dose in this specific rat protocol, gemfibrozil is a lipid-focused drug not primarily selected for weight or glucose effects, and a single non-blinded rat study is not how relative drug efficacy is actually established even between two approved medications, let alone between a drug and an unstandardized plant extract. The honest summary is: real effect, real comparator, genuinely interesting mechanism proposal, and a "beat the standard drug" framing that a single preclinical study of this kind cannot support on its own.
Bark Extract as a Nanoparticle-Synthesis Platform
A 2025 paper (Dharavath and colleagues, Drug Research) used stem bark extract of Bombax ceiba as a "green" reducing and stabilizing agent to synthesize silver nanoparticles, then characterized and therapeutically assessed the resulting nanoparticles. This is a materials-chemistry application — the bark's polyphenol content is being used as a manufacturing reagent to make a nanoparticle product, and any resulting antibacterial or other activity is a property of the silver nanoparticle, not a property of the bark extract taken as a herbal preparation. It is included here for completeness and because it explains why "silver nanoparticle" sometimes appears alongside this plant's name in search results; it is not evidence that eating or drinking bark preparations does anything.
Reading These Findings Together, Honestly
Stem bark is, by a real margin, the most pharmacologically active-looking part of this tree in the published literature — four genuinely distinct positive rat/cell findings (hypotensive constituents, anti-osteoporotic activity with a real drug comparator, anti-obesity activity with a real drug comparator, and antibacterial screening), plus a fifth paper that is chemistry only (shamiminol). That breadth is worth taking seriously as a signal that this part of the plant rewards further study. It is equally worth being clear about what it is not: not one of these findings has been tested in a human, not one has been independently replicated by a second laboratory, and two of the most eye-catching results (the osteoporosis and obesity papers) are single studies each, not converging bodies of evidence, however good their internal design. "More interesting than most of the rest of this plant's literature" and "established therapy" remain very different claims.
Cautions and Practical Guidance
- No human dosing data exists for bark preparations at any indication. The rat doses described above (100–400 mg/kg extract) do not translate to a human dose by any validated method.
- Blood pressure and blood glucose medication: the bark's hypotensive constituents add to the leaf-derived shamimin signal already flagged on the hub page — two independent reasons, from two different parts, for caution about combining bark preparations with prescribed blood-pressure or glucose-lowering drugs.
- Do not substitute bark preparations for prescribed osteoporosis therapy (raloxifene, bisphosphonates) or for prescribed lipid-lowering therapy. Both conditions have real, monitored, evidence-based treatments; unstandardized bark powder has neither a validated dose nor monitoring parameters.
- Product standardization does not exist. None of the studies above used a commercially available, standardized extract; a bark powder or tincture bought from a herbal supplier is not equivalent to the specific petroleum-ether or methanolic laboratory extracts these studies tested.
- Pregnancy and breastfeeding: no safety data exist; avoid.
Key Research Papers
- Saleem R et al. (2003). Hypotensive activity and toxicology of constituents from Bombax ceiba stem bark. Biological & Pharmaceutical Bulletin, 26(1). — PubMed
- Faizi S, Zikr-Ur-Rehman S, Versiani MA (2011). Shamiminol: a new aromatic glycoside from the stem bark of Bombax ceiba. Natural Product Communications, 6(12):1897-900. Structure-only; no bioactivity reported. — PubMed
- Masood-Ur-Rehman et al. (2017). Antibacterial and antioxidant potential of stem bark extract of Bombax ceiba collected locally from South Punjab area of Pakistan. African Journal of Traditional, Complementary, and Alternative Medicines. — PubMed
- Shah SS et al. (2018). Report: Phytochemical screening and antimicrobial activities of red silk cotton tree (Bombax ceiba L.). Pakistan Journal of Pharmaceutical Sciences, 31(3):947-952. Stem bark extracts, disc-diffusion assay. — PubMed
- Chauhan S et al. (2018). In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC. BMC Complementary and Alternative Medicine, 18(1):233. Ovariectomized rat model, raloxifene comparator. — PubMed
- Gupta P, Goyal R, Chauhan Y, Sharma PL (2013). Possible modulation of FAS and PTP-1B signaling in ameliorative potential of Bombax ceiba against high fat diet induced obesity. BMC Complementary and Alternative Medicine, 13:281. High-fat-diet rat model, gemfibrozil comparator. — PubMed
- Dharavath N et al. (2025). Characterization and Therapeutic Assessment of Phytomediated Silver Nanoparticles Produced from the Stem Bark of Bombax ceiba. Drug Research. Materials-chemistry application, not a herbal-preparation finding. — PubMed
- Faizi S et al. (1999). Shamimin: a new flavonol C-glycoside from leaves of Bombax ceiba. Planta Medica, 65(4). Cross-referenced from the hub page — leaf, not bark; the compound shamiminol (above) is unrelated to this one despite the similar name. — PubMed
PubMed Topic Searches
- PubMed: All Bombax ceiba stem bark constituent literature
- PubMed: Raloxifene in ovariectomized bone-density models (comparator context)